Bo‐Sheng Pan

Infrared Laboratories (United States) — United States

Medicine · Health Sciences

16h-index2.9kcitations77works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver physiology and pathology(30), PI3K/AKT/mTOR signaling in cancer(14), interferon and immune responses(13), Cancer Immunotherapy and Biomarkers(8), Lung Cancer Treatments and Mutations(7)

Publications77 total

Abstract 5703: Development of RVL-101, a CDK4/6-selective, small molecule inhibitor with superior CNS penetration and combinability potential for the effective treatment of primary and metastatic brain tumors
Cancer Research·2024
Supplementary Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S2 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Table S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Supplementary Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Table S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S2 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S3 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S3 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Data from MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs <i>In vitro</i> and <i>In vivo</i>
2023Open Access
Supplementary Data from MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs <i>In vitro</i> and <i>In vivo</i>
2023Open Access
Supplementary Data from MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs <i>In vitro</i> and <i>In vivo</i>
2023Open Access
Data from MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs <i>In vitro</i> and <i>In vivo</i>
2023Open Access
Supplementary Information from Lung Cancer Cell Lines Harboring <i>MET</i> Gene Amplification Are Dependent on Met for Growth and Survival
2023Open Access
Supplementary Methods, Table 1, Figure Legends 1-5 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 1 Legend from Lung Cancer Cell Lines Harboring <i>MET</i> Gene Amplification Are Dependent on Met for Growth and Survival
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Bart Lutterbach(19), Harold Hatch(18), Lenora J. Davis(18), Gaozhen Hang(16), Qinwen Zeng(15), Nancy E. Kohl(15), W. Wayt Gibbs(14), Sujal V. Deshmukh(14), Ilona Kariv(12), Jennifer Piesvaux(11), John F. Reilly(11), Alexander A. Szewczak(11), Christopher J. Dinsmore(11), Samanthi A. Perera(10), Jeremy Presland(10), Jared N. Cumming(10), Sašo Čemerski(10), James P. Jewell(10), Ian Knemeyer(10), Johnny E. Kopinja(10)